Review



scc25 cells  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    ATCC scc25 cells
    Analgesic effects of Rimegepant in OSCC-associated pain demonstrated via the unilateral tongue orthotopic transplantation model. A Construction of the unilateral tongue orthotopic transplantation model and drug injection with mechanical threshold measurement protocol. B Following tumor transplantation, the differences in mechanical sensitivity between the transplanted ( n = 14) and non-transplanted ( n = 10) sides were compared using unpaired two-tailed Student’s t test. C Changes in sensitivity 1 h after Rimegepant (50 mg/kg), Rimegepant (10 mg/kg) and Carprofen treatment were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). D Changes in sensitivity following Rimegepant (50 mg/kg) and Tramadol treatment at 1 h were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). E The 4-day trends of facial mechanical sensitivities 24 h after Rimegepant (50 mg/kg) and Tramadol treatment. ( n = 6–8/group). F Changes in sensitivity 1 h after Tramadol, Carprofen treatment and local lingual injection of Rimegepant (10 mg/kg) in CAL27 and <t>SCC25</t> xenograft models were performed using one-way ANOVA( n = 8). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, ns P > 0.05
    Scc25 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1324 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/scc+25+cells/pmc13173713-52-4-10?v=ATCC
    Average 97 stars, based on 1324 article reviews
    scc25 cells - by Bioz Stars, 2026-07
    97/100 stars

    Images

    1) Product Images from "Targeting CGRP signaling alleviates cancer-associated pain in oral squamous cell carcinoma"

    Article Title: Targeting CGRP signaling alleviates cancer-associated pain in oral squamous cell carcinoma

    Journal: BMC Oral Health

    doi: 10.1186/s12903-026-08444-x

    Analgesic effects of Rimegepant in OSCC-associated pain demonstrated via the unilateral tongue orthotopic transplantation model. A Construction of the unilateral tongue orthotopic transplantation model and drug injection with mechanical threshold measurement protocol. B Following tumor transplantation, the differences in mechanical sensitivity between the transplanted ( n = 14) and non-transplanted ( n = 10) sides were compared using unpaired two-tailed Student’s t test. C Changes in sensitivity 1 h after Rimegepant (50 mg/kg), Rimegepant (10 mg/kg) and Carprofen treatment were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). D Changes in sensitivity following Rimegepant (50 mg/kg) and Tramadol treatment at 1 h were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). E The 4-day trends of facial mechanical sensitivities 24 h after Rimegepant (50 mg/kg) and Tramadol treatment. ( n = 6–8/group). F Changes in sensitivity 1 h after Tramadol, Carprofen treatment and local lingual injection of Rimegepant (10 mg/kg) in CAL27 and SCC25 xenograft models were performed using one-way ANOVA( n = 8). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, ns P > 0.05
    Figure Legend Snippet: Analgesic effects of Rimegepant in OSCC-associated pain demonstrated via the unilateral tongue orthotopic transplantation model. A Construction of the unilateral tongue orthotopic transplantation model and drug injection with mechanical threshold measurement protocol. B Following tumor transplantation, the differences in mechanical sensitivity between the transplanted ( n = 14) and non-transplanted ( n = 10) sides were compared using unpaired two-tailed Student’s t test. C Changes in sensitivity 1 h after Rimegepant (50 mg/kg), Rimegepant (10 mg/kg) and Carprofen treatment were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). D Changes in sensitivity following Rimegepant (50 mg/kg) and Tramadol treatment at 1 h were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). E The 4-day trends of facial mechanical sensitivities 24 h after Rimegepant (50 mg/kg) and Tramadol treatment. ( n = 6–8/group). F Changes in sensitivity 1 h after Tramadol, Carprofen treatment and local lingual injection of Rimegepant (10 mg/kg) in CAL27 and SCC25 xenograft models were performed using one-way ANOVA( n = 8). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, ns P > 0.05

    Techniques Used: Transplantation Assay, Injection, Two Tailed Test



    Similar Products

    97
    ATCC scc25 cells
    Analgesic effects of Rimegepant in OSCC-associated pain demonstrated via the unilateral tongue orthotopic transplantation model. A Construction of the unilateral tongue orthotopic transplantation model and drug injection with mechanical threshold measurement protocol. B Following tumor transplantation, the differences in mechanical sensitivity between the transplanted ( n = 14) and non-transplanted ( n = 10) sides were compared using unpaired two-tailed Student’s t test. C Changes in sensitivity 1 h after Rimegepant (50 mg/kg), Rimegepant (10 mg/kg) and Carprofen treatment were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). D Changes in sensitivity following Rimegepant (50 mg/kg) and Tramadol treatment at 1 h were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). E The 4-day trends of facial mechanical sensitivities 24 h after Rimegepant (50 mg/kg) and Tramadol treatment. ( n = 6–8/group). F Changes in sensitivity 1 h after Tramadol, Carprofen treatment and local lingual injection of Rimegepant (10 mg/kg) in CAL27 and <t>SCC25</t> xenograft models were performed using one-way ANOVA( n = 8). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, ns P > 0.05
    Scc25 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/scc+25+cells/pmc13173713-52-4-10?v=ATCC
    Average 97 stars, based on 1 article reviews
    scc25 cells - by Bioz Stars, 2026-07
    97/100 stars
      Buy from Supplier

    97
    ATCC scc 25 cells
    Analgesic effects of Rimegepant in OSCC-associated pain demonstrated via the unilateral tongue orthotopic transplantation model. A Construction of the unilateral tongue orthotopic transplantation model and drug injection with mechanical threshold measurement protocol. B Following tumor transplantation, the differences in mechanical sensitivity between the transplanted ( n = 14) and non-transplanted ( n = 10) sides were compared using unpaired two-tailed Student’s t test. C Changes in sensitivity 1 h after Rimegepant (50 mg/kg), Rimegepant (10 mg/kg) and Carprofen treatment were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). D Changes in sensitivity following Rimegepant (50 mg/kg) and Tramadol treatment at 1 h were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). E The 4-day trends of facial mechanical sensitivities 24 h after Rimegepant (50 mg/kg) and Tramadol treatment. ( n = 6–8/group). F Changes in sensitivity 1 h after Tramadol, Carprofen treatment and local lingual injection of Rimegepant (10 mg/kg) in CAL27 and <t>SCC25</t> xenograft models were performed using one-way ANOVA( n = 8). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, ns P > 0.05
    Scc 25 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/scc+25+cells/pm42021215-96-0-3?v=ATCC
    Average 97 stars, based on 1 article reviews
    scc 25 cells - by Bioz Stars, 2026-07
    97/100 stars
      Buy from Supplier

    97
    ATCC scc 25 crl 1628 cells
    Analgesic effects of Rimegepant in OSCC-associated pain demonstrated via the unilateral tongue orthotopic transplantation model. A Construction of the unilateral tongue orthotopic transplantation model and drug injection with mechanical threshold measurement protocol. B Following tumor transplantation, the differences in mechanical sensitivity between the transplanted ( n = 14) and non-transplanted ( n = 10) sides were compared using unpaired two-tailed Student’s t test. C Changes in sensitivity 1 h after Rimegepant (50 mg/kg), Rimegepant (10 mg/kg) and Carprofen treatment were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). D Changes in sensitivity following Rimegepant (50 mg/kg) and Tramadol treatment at 1 h were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). E The 4-day trends of facial mechanical sensitivities 24 h after Rimegepant (50 mg/kg) and Tramadol treatment. ( n = 6–8/group). F Changes in sensitivity 1 h after Tramadol, Carprofen treatment and local lingual injection of Rimegepant (10 mg/kg) in CAL27 and <t>SCC25</t> xenograft models were performed using one-way ANOVA( n = 8). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, ns P > 0.05
    Scc 25 Crl 1628 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/scc+25+cells/bio_rxiv__64898__2026__04__02__716058-50-3-10?v=ATCC
    Average 97 stars, based on 1 article reviews
    scc 25 crl 1628 cells - by Bioz Stars, 2026-07
    97/100 stars
      Buy from Supplier

    97
    ATCC scc 25 tongue squamous cell carcinoma
    Analgesic effects of Rimegepant in OSCC-associated pain demonstrated via the unilateral tongue orthotopic transplantation model. A Construction of the unilateral tongue orthotopic transplantation model and drug injection with mechanical threshold measurement protocol. B Following tumor transplantation, the differences in mechanical sensitivity between the transplanted ( n = 14) and non-transplanted ( n = 10) sides were compared using unpaired two-tailed Student’s t test. C Changes in sensitivity 1 h after Rimegepant (50 mg/kg), Rimegepant (10 mg/kg) and Carprofen treatment were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). D Changes in sensitivity following Rimegepant (50 mg/kg) and Tramadol treatment at 1 h were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). E The 4-day trends of facial mechanical sensitivities 24 h after Rimegepant (50 mg/kg) and Tramadol treatment. ( n = 6–8/group). F Changes in sensitivity 1 h after Tramadol, Carprofen treatment and local lingual injection of Rimegepant (10 mg/kg) in CAL27 and <t>SCC25</t> xenograft models were performed using one-way ANOVA( n = 8). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, ns P > 0.05
    Scc 25 Tongue Squamous Cell Carcinoma, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/scc+25+cells/us12589163-1142-16-25?v=ATCC
    Average 97 stars, based on 1 article reviews
    scc 25 tongue squamous cell carcinoma - by Bioz Stars, 2026-07
    97/100 stars
      Buy from Supplier

    97
    ATCC oscc cell lines scc25
    Analgesic effects of Rimegepant in OSCC-associated pain demonstrated via the unilateral tongue orthotopic transplantation model. A Construction of the unilateral tongue orthotopic transplantation model and drug injection with mechanical threshold measurement protocol. B Following tumor transplantation, the differences in mechanical sensitivity between the transplanted ( n = 14) and non-transplanted ( n = 10) sides were compared using unpaired two-tailed Student’s t test. C Changes in sensitivity 1 h after Rimegepant (50 mg/kg), Rimegepant (10 mg/kg) and Carprofen treatment were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). D Changes in sensitivity following Rimegepant (50 mg/kg) and Tramadol treatment at 1 h were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). E The 4-day trends of facial mechanical sensitivities 24 h after Rimegepant (50 mg/kg) and Tramadol treatment. ( n = 6–8/group). F Changes in sensitivity 1 h after Tramadol, Carprofen treatment and local lingual injection of Rimegepant (10 mg/kg) in CAL27 and <t>SCC25</t> xenograft models were performed using one-way ANOVA( n = 8). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, ns P > 0.05
    Oscc Cell Lines Scc25, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/scc+25+cells/pm41896711-56-12-34?v=ATCC
    Average 97 stars, based on 1 article reviews
    oscc cell lines scc25 - by Bioz Stars, 2026-07
    97/100 stars
      Buy from Supplier

    86
    Procell Inc scc 25 cells
    Analgesic effects of Rimegepant in OSCC-associated pain demonstrated via the unilateral tongue orthotopic transplantation model. A Construction of the unilateral tongue orthotopic transplantation model and drug injection with mechanical threshold measurement protocol. B Following tumor transplantation, the differences in mechanical sensitivity between the transplanted ( n = 14) and non-transplanted ( n = 10) sides were compared using unpaired two-tailed Student’s t test. C Changes in sensitivity 1 h after Rimegepant (50 mg/kg), Rimegepant (10 mg/kg) and Carprofen treatment were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). D Changes in sensitivity following Rimegepant (50 mg/kg) and Tramadol treatment at 1 h were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). E The 4-day trends of facial mechanical sensitivities 24 h after Rimegepant (50 mg/kg) and Tramadol treatment. ( n = 6–8/group). F Changes in sensitivity 1 h after Tramadol, Carprofen treatment and local lingual injection of Rimegepant (10 mg/kg) in CAL27 and <t>SCC25</t> xenograft models were performed using one-way ANOVA( n = 8). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, ns P > 0.05
    Scc 25 Cells, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/scc+25+cells/pm41905100-95-0-3?v=Procell+Inc
    Average 86 stars, based on 1 article reviews
    scc 25 cells - by Bioz Stars, 2026-07
    86/100 stars
      Buy from Supplier

    97
    ATCC pr es s human hnscc cell lines scc25
    Analgesic effects of Rimegepant in OSCC-associated pain demonstrated via the unilateral tongue orthotopic transplantation model. A Construction of the unilateral tongue orthotopic transplantation model and drug injection with mechanical threshold measurement protocol. B Following tumor transplantation, the differences in mechanical sensitivity between the transplanted ( n = 14) and non-transplanted ( n = 10) sides were compared using unpaired two-tailed Student’s t test. C Changes in sensitivity 1 h after Rimegepant (50 mg/kg), Rimegepant (10 mg/kg) and Carprofen treatment were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). D Changes in sensitivity following Rimegepant (50 mg/kg) and Tramadol treatment at 1 h were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). E The 4-day trends of facial mechanical sensitivities 24 h after Rimegepant (50 mg/kg) and Tramadol treatment. ( n = 6–8/group). F Changes in sensitivity 1 h after Tramadol, Carprofen treatment and local lingual injection of Rimegepant (10 mg/kg) in CAL27 and <t>SCC25</t> xenograft models were performed using one-way ANOVA( n = 8). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, ns P > 0.05
    Pr Es S Human Hnscc Cell Lines Scc25, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/scc+25+cells/pm41765937-100-8-25?v=ATCC
    Average 97 stars, based on 1 article reviews
    pr es s human hnscc cell lines scc25 - by Bioz Stars, 2026-07
    97/100 stars
      Buy from Supplier

    97
    ATCC human hnscc cell line scc25
    LIS1 increases the migration, invasion, and PNI capability of HNSCC cells. ( A ) Wound healing assay of LIS1 overexpression or LIS1 knockdown in <t>SCC25</t> cells. ( B ) Transwell assay of LIS1 overexpression or LIS1 knockdown in SCC25 cells. ( C ) Representative images of the in vitro PNI model for LIS1 overexpression or LIS1 knockdown in SCC25 cells. ( D ) Microfluidic chip pattern diagram and representative images of LIS1 overexpression or LIS1 knockdown in SCC25 cells co-cultured with SCs in the microfluidic chip. Data are represented as mean ± SEM, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001
    Human Hnscc Cell Line Scc25, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/scc+25+cells/pmc13059471-65-0-14?v=ATCC
    Average 97 stars, based on 1 article reviews
    human hnscc cell line scc25 - by Bioz Stars, 2026-07
    97/100 stars
      Buy from Supplier

    Image Search Results


    Analgesic effects of Rimegepant in OSCC-associated pain demonstrated via the unilateral tongue orthotopic transplantation model. A Construction of the unilateral tongue orthotopic transplantation model and drug injection with mechanical threshold measurement protocol. B Following tumor transplantation, the differences in mechanical sensitivity between the transplanted ( n = 14) and non-transplanted ( n = 10) sides were compared using unpaired two-tailed Student’s t test. C Changes in sensitivity 1 h after Rimegepant (50 mg/kg), Rimegepant (10 mg/kg) and Carprofen treatment were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). D Changes in sensitivity following Rimegepant (50 mg/kg) and Tramadol treatment at 1 h were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). E The 4-day trends of facial mechanical sensitivities 24 h after Rimegepant (50 mg/kg) and Tramadol treatment. ( n = 6–8/group). F Changes in sensitivity 1 h after Tramadol, Carprofen treatment and local lingual injection of Rimegepant (10 mg/kg) in CAL27 and SCC25 xenograft models were performed using one-way ANOVA( n = 8). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, ns P > 0.05

    Journal: BMC Oral Health

    Article Title: Targeting CGRP signaling alleviates cancer-associated pain in oral squamous cell carcinoma

    doi: 10.1186/s12903-026-08444-x

    Figure Lengend Snippet: Analgesic effects of Rimegepant in OSCC-associated pain demonstrated via the unilateral tongue orthotopic transplantation model. A Construction of the unilateral tongue orthotopic transplantation model and drug injection with mechanical threshold measurement protocol. B Following tumor transplantation, the differences in mechanical sensitivity between the transplanted ( n = 14) and non-transplanted ( n = 10) sides were compared using unpaired two-tailed Student’s t test. C Changes in sensitivity 1 h after Rimegepant (50 mg/kg), Rimegepant (10 mg/kg) and Carprofen treatment were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). D Changes in sensitivity following Rimegepant (50 mg/kg) and Tramadol treatment at 1 h were performed using one-way ANOVA. Each dataset included results from monitoring over 4 consecutive days ( n = 6–8/group). E The 4-day trends of facial mechanical sensitivities 24 h after Rimegepant (50 mg/kg) and Tramadol treatment. ( n = 6–8/group). F Changes in sensitivity 1 h after Tramadol, Carprofen treatment and local lingual injection of Rimegepant (10 mg/kg) in CAL27 and SCC25 xenograft models were performed using one-way ANOVA( n = 8). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, ns P > 0.05

    Article Snippet: Human OSCC CAL27 and SCC25 cells were purchased from the American Type Culture Collection (USA).

    Techniques: Transplantation Assay, Injection, Two Tailed Test

    LIS1 increases the migration, invasion, and PNI capability of HNSCC cells. ( A ) Wound healing assay of LIS1 overexpression or LIS1 knockdown in SCC25 cells. ( B ) Transwell assay of LIS1 overexpression or LIS1 knockdown in SCC25 cells. ( C ) Representative images of the in vitro PNI model for LIS1 overexpression or LIS1 knockdown in SCC25 cells. ( D ) Microfluidic chip pattern diagram and representative images of LIS1 overexpression or LIS1 knockdown in SCC25 cells co-cultured with SCs in the microfluidic chip. Data are represented as mean ± SEM, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001

    Journal: Cancer Cell International

    Article Title: LIS1 mediated Schwann cell reprogramming enhances perineural invasion by activating the serine/NMDAR/AKT signaling pathway in head and neck squamous carcinoma

    doi: 10.1186/s12935-026-04243-0

    Figure Lengend Snippet: LIS1 increases the migration, invasion, and PNI capability of HNSCC cells. ( A ) Wound healing assay of LIS1 overexpression or LIS1 knockdown in SCC25 cells. ( B ) Transwell assay of LIS1 overexpression or LIS1 knockdown in SCC25 cells. ( C ) Representative images of the in vitro PNI model for LIS1 overexpression or LIS1 knockdown in SCC25 cells. ( D ) Microfluidic chip pattern diagram and representative images of LIS1 overexpression or LIS1 knockdown in SCC25 cells co-cultured with SCs in the microfluidic chip. Data are represented as mean ± SEM, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001

    Article Snippet: Human HNSCC cell line (SCC25) and human Schwann cells (sNF96.2) were acquired from the American Type Culture Collection (ATCC, Manassas, VA, USA) in 2023.

    Techniques: Migration, Wound Healing Assay, Over Expression, Knockdown, Transwell Assay, In Vitro, Cell Culture

    LIS1 overexpression of HNSCC cells increases Schwann cells activity. ( A ) The pattern diagram of HNSCC cells co-cultured with SCs. ( B ) Transwell assay of sNF96.2 cells co-cultured with SCC25 cells. ( C ) The mRNA expression of PNI-related factors (BDNF, GDNF, NGF, MMP2, and MMP9) in sNF96.2 cells co-cultured with SCC25 cells were analyzed by RT-qPCR. ( D ) IF double staining was performed to detect the expression of S100 and GFAP in the sNF96.2 cells co-cultured with SCC25 cells. Data are represented as mean ± SEM, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001

    Journal: Cancer Cell International

    Article Title: LIS1 mediated Schwann cell reprogramming enhances perineural invasion by activating the serine/NMDAR/AKT signaling pathway in head and neck squamous carcinoma

    doi: 10.1186/s12935-026-04243-0

    Figure Lengend Snippet: LIS1 overexpression of HNSCC cells increases Schwann cells activity. ( A ) The pattern diagram of HNSCC cells co-cultured with SCs. ( B ) Transwell assay of sNF96.2 cells co-cultured with SCC25 cells. ( C ) The mRNA expression of PNI-related factors (BDNF, GDNF, NGF, MMP2, and MMP9) in sNF96.2 cells co-cultured with SCC25 cells were analyzed by RT-qPCR. ( D ) IF double staining was performed to detect the expression of S100 and GFAP in the sNF96.2 cells co-cultured with SCC25 cells. Data are represented as mean ± SEM, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001

    Article Snippet: Human HNSCC cell line (SCC25) and human Schwann cells (sNF96.2) were acquired from the American Type Culture Collection (ATCC, Manassas, VA, USA) in 2023.

    Techniques: Over Expression, Activity Assay, Cell Culture, Transwell Assay, Expressing, Quantitative RT-PCR, Double Staining

    LIS1 overexpression activates the serine signaling pathway to promote the PNI in HNSCC cells. ( A ) The mRNA expression of PHGDH, PSAT1, and PSPH in SCC25 cells were analyzed by RT-qPCR. ( B ) Analysis of the relative intracellular serine levels in SCC25 cells. ( C ) The protein level of PHGDH, PSAT1, and PSPH in SCC25 cells were analyzed by WB. ( D ) Migration and invasion assay of shLIS1 group after exogenous serine stimulation of SCC25 cells and quantitative analysis. ( E ) Representative images of the in vitro PNI model for shLIS1 group after exogenous serine stimulation of SCC25 cells and the analysis of neural invasion index. ( F ) Representative images of the microfluidic chip for shLIS1 group after exogenous serine stimulation of SCC25 cells and analysis of migration distance. Data are represented as mean ± SEM, ** P < 0.01, *** P < 0.001, **** P < 0.0001

    Journal: Cancer Cell International

    Article Title: LIS1 mediated Schwann cell reprogramming enhances perineural invasion by activating the serine/NMDAR/AKT signaling pathway in head and neck squamous carcinoma

    doi: 10.1186/s12935-026-04243-0

    Figure Lengend Snippet: LIS1 overexpression activates the serine signaling pathway to promote the PNI in HNSCC cells. ( A ) The mRNA expression of PHGDH, PSAT1, and PSPH in SCC25 cells were analyzed by RT-qPCR. ( B ) Analysis of the relative intracellular serine levels in SCC25 cells. ( C ) The protein level of PHGDH, PSAT1, and PSPH in SCC25 cells were analyzed by WB. ( D ) Migration and invasion assay of shLIS1 group after exogenous serine stimulation of SCC25 cells and quantitative analysis. ( E ) Representative images of the in vitro PNI model for shLIS1 group after exogenous serine stimulation of SCC25 cells and the analysis of neural invasion index. ( F ) Representative images of the microfluidic chip for shLIS1 group after exogenous serine stimulation of SCC25 cells and analysis of migration distance. Data are represented as mean ± SEM, ** P < 0.01, *** P < 0.001, **** P < 0.0001

    Article Snippet: Human HNSCC cell line (SCC25) and human Schwann cells (sNF96.2) were acquired from the American Type Culture Collection (ATCC, Manassas, VA, USA) in 2023.

    Techniques: Over Expression, Expressing, Quantitative RT-PCR, Migration, Invasion Assay, In Vitro